Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDLELIT-015: MK-1084 plus durvalumab versus placebo plus durvalumab after chemoradiotherapy for unresectable locally advanced KRAS G12C-mutant non-small cell lung cancer
CTR20262390Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of calderasib, durvalumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Jun 2026; status: active.
02
Drugs
calderasibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262390.